Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers (CSCPDPC -CCs) (U01)
The summary for the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers (CSCPDPC -CCs) (U01) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers (CSCPDPC -CCs) (U01): This Funding Opportunity Announcement (FOA) invites U01 applications for the establishment of a clinical consortium, composed of one Coordination and Data Management Center (CDMC) and up to 9 Clinical Centers (CC), to conduct studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes.
The Consortium will form multi-disciplinary teams composed of members from the CCs and CDMC to undertake a comprehensive clinical, epidemiological and biological characterization of patients with CP (including those with Acute Recurrent Pancreatitis, ARP) to gain insight into the pathophysiology of chronic pancreatitis and its sequela: chronic pain, pancreatic insufficiency, T3cDM and the diabetes/pancreatic cancer association. The teams will also undertake studies on the development of pancreatic cancer in newly diagnosed diabetic patients.
Applications for the Consortium Coordination and Data Management Center (CDMC) are being solicited via RFA-DK-14-028 "Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Coordinating Center (CSCPDPC-CDMC) (U01)".
To achieve the goal of a comprehensive characterization of evolving chronic pancreatitis and pancreatic cancer, each CC should include researchers and clinicians with multi-disciplinary expertise. Research CCs will be expected to share results freely within Consortium and to develop trans-Consortium collaborative projects that make use of the combined expertise and technological capabilities present in all of the CCs.
In addition, a major collaborative effort within the Consortium will be the establishment of an annotated repository of biospecimens (blood, pancreatic and duodenal juice, stools and when feasible pancreatic tissue) to allow for the identification and validation of biomarkers for risk stratification and/or early detection.
The Consortium will form multi-disciplinary teams composed of members from the CCs and CDMC to undertake a comprehensive clinical, epidemiological and biological characterization of patients with CP (including those with Acute Recurrent Pancreatitis, ARP) to gain insight into the pathophysiology of chronic pancreatitis and its sequela: chronic pain, pancreatic insufficiency, T3cDM and the diabetes/pancreatic cancer association. The teams will also undertake studies on the development of pancreatic cancer in newly diagnosed diabetic patients.
Applications for the Consortium Coordination and Data Management Center (CDMC) are being solicited via RFA-DK-14-028 "Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Coordinating Center (CSCPDPC-CDMC) (U01)".
To achieve the goal of a comprehensive characterization of evolving chronic pancreatitis and pancreatic cancer, each CC should include researchers and clinicians with multi-disciplinary expertise. Research CCs will be expected to share results freely within Consortium and to develop trans-Consortium collaborative projects that make use of the combined expertise and technological capabilities present in all of the CCs.
In addition, a major collaborative effort within the Consortium will be the establishment of an annotated repository of biospecimens (blood, pancreatic and duodenal juice, stools and when feasible pancreatic tissue) to allow for the identification and validation of biomarkers for risk stratification and/or early detection.
Federal Grant Title: | Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers (CSCPDPC -CCs) (U01) |
Federal Agency Name: | National Institutes of Health |
Grant Categories: | Education Food and Nutrition Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-DK-14-027 |
Type of Funding: | Cooperative Agreement |
CFDA Numbers: | 93.393, 93.399, 93.847 |
CFDA Descriptions: | Cancer Cause and Prevention Research; Cancer Control; Diabetes, Digestive, and Kidney Diseases Extramural Research |
Current Application Deadline: | Apr 2, 2015 |
Original Application Deadline: | Apr 2, 2015 |
Posted Date: | October 17th, 2014 |
Creation Date: | Oct 17, 2014 |
Archive Date: | May 3, 2015 |
Total Program Funding: | $6,000,000 |
Maximum Federal Grant Award: | $270,000 |
Minimum Federal Grant Award: | none |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- For profit organizations other than small businesses
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
Small businesses
Native American tribal organizations (other than Federally recognized tribal governments)
Special district governments
State governments
Public and State controlled institutions of higher education
County governments
Independent school districts
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Public housing authorities/Indian housing authorities
City or township governments
Native American tribal governments (Federally recognized) - Additional Information on Eligibility
- Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-14-027.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
National Institutes of Health 301-496-3405 - Similar Government Grants
- • Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)
- • Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)
- • Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed...
- • Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)
- • NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)
- • Pilot Studies in Pancreatic Cancer
- • Cancer Prevention Research Small Grant Program
- • Molecular Targets for Nutrients in Prostate Cancer Prevention
- More Grants from the National Institutes of Health
- • HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...
- • Cellular Models of HIV Pathogenesis within NIDDK Mission Areas (R01 Clinical Trial Not All...
- • U.S.-South Africa Program for Collaborative Biomedical Research Phase 3 (HIV/AIDS) (R01 C...
- • Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Option...
- • Research Centers in Minority Institutions (RCMI) (U54 - Clinical Trial Optional)